95 related articles for article (PubMed ID: 23545664)
1. Comparison of the efficacies of irbesartan and olmesartan after successful coronary stent implantation.
Morii J; Miura S; Ike A; Shiga Y; Sugihara M; Iwata A; Kawamura A; Nishikawa H; Saku K
Intern Med; 2013; 52(7):713-9. PubMed ID: 23545664
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).
Morii J; Miura S; Shiga Y; Sugihara M; Arimura T; Sako H; Zhang B; Uehara Y; Saku K
Clin Exp Hypertens; 2012; 34(5):342-9. PubMed ID: 22568596
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation.
Sugihara M; Miura S; Takamiya Y; Kiya Y; Arimura T; Iwata A; Kawamura A; Nishikawa H; Uehara Y; Saku K
Hypertens Res; 2009 Jul; 32(7):625-30. PubMed ID: 19461652
[TBL] [Abstract][Full Text] [Related]
4. Effect of olmesartan on the levels of circulating endothelial progenitor cell after drug-eluting stent implantation in patients receiving statin therapy.
Aoki J; Kozuma K; Tanabe K; Tanimoto S; Nakajima Y; Yahagi K; Hashimoto T; Isshiki T; Hara K
J Cardiol; 2014 Dec; 64(6):435-40. PubMed ID: 24768407
[TBL] [Abstract][Full Text] [Related]
5. Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
Jones MR; Sealey JE; Laragh JH
Am J Hypertens; 2007 Aug; 20(8):907-16. PubMed ID: 17679042
[TBL] [Abstract][Full Text] [Related]
6. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Palatini P; Jung W; Shlyakhto E; Botha J; Bush C; Keefe DL
J Hum Hypertens; 2010 Feb; 24(2):93-103. PubMed ID: 19458624
[TBL] [Abstract][Full Text] [Related]
7. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
Bobrie G;
Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of the effect of an angiotensin II receptor blocker SR47436 (irbesartan) on 24-hour blood pressure in patients with essential hypertension.
Kawano Y; Sato Y; Yoshinaga K
Hypertens Res; 2008 Sep; 31(9):1753-63. PubMed ID: 18971554
[TBL] [Abstract][Full Text] [Related]
9. Effects of aerobic exercise training and irbesartan on blood pressure and heart rate variability in patients with chronic obstructive pulmonary disease.
Marquis K; Maltais F; Lacasse Y; Lacourciere Y; Fortin C; Poirier P
Can Respir J; 2008 Oct; 15(7):355-60. PubMed ID: 18949104
[TBL] [Abstract][Full Text] [Related]
10. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension.
Shiga Y; Miura SI; Motozato K; Norimatsu K; Yano M; Hitaka Y; Adachi S; Kuwano T; Inoue K; Inoue A; Fujisawa K; Shirotani T; Kusumoto T; Ideishi M; Saku K
Int Heart J; 2017 May; 58(3):416-421. PubMed ID: 28496022
[TBL] [Abstract][Full Text] [Related]
12. Effects of estradiol and the angiotensin II receptor blocker irbesartan on vascular function in postmenopausal women.
Mirza FS; Ong P; Collins P; Okamura K; Gerhard-Herman M; Williams GH; Seely EW
Menopause; 2008; 15(1):44-50. PubMed ID: 18182939
[TBL] [Abstract][Full Text] [Related]
13. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
Zannad F; Fay R
Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
[TBL] [Abstract][Full Text] [Related]
14. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
15. Effect of Olmesartan on serum cystatin C levels in the patients with essential hypertension.
Koc Y; Mazi E; Sakaci T; Basturk T; Damar AB; Ahbap E; Unsal A; Borlu F
Eur Rev Med Pharmacol Sci; 2011 Dec; 15(12):1389-94. PubMed ID: 22288300
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
17. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study.
Vitale C; Marazzi G; Iellamo F; Spoletini I; Dall'Armi V; Fini M; Volterrani M
Int J Cardiol; 2012 Mar; 155(2):279-84. PubMed ID: 22078979
[TBL] [Abstract][Full Text] [Related]
18. Relationship between the frequency of blood pressure self-measurement and blood pressure reduction with antihypertensive therapy : results of the OLMETEL (OLMEsartan TELemonitoring blood pressure) study.
Ewald S; vor dem Esche J; Uen S; Neikes F; Vetter H; Mengden T
Clin Drug Investig; 2006; 26(8):439-46. PubMed ID: 17163276
[TBL] [Abstract][Full Text] [Related]
19. Protective effect of angiotensin II receptor blocker and calcium channel blocker on endothelial vasomotor function after everolimus-eluting stent implantation.
Aoki Y; Ishikawa K; Miura K; Sugimoto K; Nakayama T; Fujimoto Y; Kobayashi Y
J Cardiol; 2016 Mar; 67(3):236-40. PubMed ID: 26194867
[TBL] [Abstract][Full Text] [Related]
20. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
Shimada K; Ogihara T; Saruta T; Kuramoto K;
Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
